Q3 2025 Vimian Group AB Earnings Call Transcript
Key Points
- Vimian Group AB (VIMGF) reported strong revenue growth of 19% in the third quarter, with 9% organic growth.
- The specialty pharma segment achieved a 25% increase in all-time high revenues for an individual quarter, with 11% organic growth.
- The company received a favorable court ruling in the US indemnification dispute, awarding them $40.2 million in damages.
- Medtech segment returned to organic growth with a 5% increase, showing recovery after a challenging second quarter.
- Vimian Group AB (VIMGF) continues to build a strong M&A pipeline, screening over 235 targets year-to-date, indicating robust future growth potential.
- The adjusted EBITDA margin decreased slightly to 24.5% from 25.0% in the same period last year, impacted by investments in the commercial organization.
- Currency movements, particularly from the US to EUR, had a negative impact of 4% on the quarter's results.
- The company's cash flow from operating activities was impacted by higher tax expenses and negative currency effects.
- The US orthopedics market remains soft, and it may take time before the full financial benefits of recovery measures are realized.
- The company's net financial items showed a negative impact of €4.1 million, including finance expenses and exchange rate effects on debt revaluation.
Welcome to the Vimian Group Q3 report 2025 presentation. (Operator Instructions)
Now I will hand the conference over to the speakers CFO and Interim CEO, Carl-Johan Zetterberg Boudrie; Magnus Kjellberg, Vivian Specialty Pharma. Please go ahead.
Good morning everyone and welcome to Vamian's 3rd quarter earnings school.
I'm Krian Saiburi, CFO and interim CEO, and with me today is Magnus Sheba, who's leading specialty pharma, our largest segment representing almost 50% of Indian.
We'll go through the quarterly results and mines will give you some additional insights to our specialty pharma segment.
We deliver strong revenue growth of 19% with 9% organic growth in the third quarter.
We also saw strong earnings growth with adjusted EBITDA up 17% in the quarter.
Both specialty pharma and veterinary services continue to deliver strong performance, and our medtech segment returned to organic
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
